Objective: To study whether exposure to childhood emotional, sexual or physical abuse is associated with subsequent multiple sclerosis (MS) development.

Objective: To study whether exposure to childhood emotional, sexual or physical abuse is associated with subsequent multiple sclerosis (MS) development.
The Parkinson’s research program led by Prof. Charalampos Tzoulis at the Neuro-SysMed Center has been strengthened by grants from the regional and national Norwegian Health Authorities, amounting to more than 3 million Euros.
The grants will fund clinical studies led by Prof. Tzoulis’ group, including NOPARK.
NOPARK is a phase II, double-blinded randomized clinical trial of NAD-replenishment therapy by oral nicotinamide riboside (NR) in Parkinson’s disease. The trial will determine whether NR has neuroprotective action and delays the motor and non-motor progression of Parkinson’s disease. A total of 400 persons with Parkinson’s disease who have had the diagnosis for up to 2 years will be recruited from all of Norway.
https://helse-bergen.no/kliniske-studier/parkinson-sykdom-behandling-med-nikotinamid-nopark-studien
Welcome to a CCBIO and Neuro-SysMed Special Seminar on Creativity & Innovation Leadership. Inspirational lectures and discussions with invited speakers Ole Dahlberg and Ingunn Johanne Ness.